DiaSorin Inc.

DiaSorin Inc. is a global leader in laboratory diagnostics, specializing in immunodiagnostics and molecular diagnostics platforms. The company develops and manufactures diagnostic assays and analyzers for infectious diseases, immunological disorders, and other clinical applications. Core product lines include the LIAISON® automated immunoassay analyzer platform, Simplexa® molecular diagnostic kits for detection of viral pathogens (COVID-19, Flu A/B, RSV, HSV, CMV), and QuantiFERON® TB Gold Plus for tuberculosis detection. DiaSorin also offers the LIAISON® MeMed BV® for rapid bacterial-viral differentiation and LIAISON® BRAHMS PCT® for infection triage. The company operates the Luminex division, providing xMAP® multiplex assay technology platforms (xMAP INTELLIFLEX®) for biomedical research, clinical diagnostics, and drug discovery applications, including custom assay design and development services. Products address hospital laboratories, clinical diagnostic centers, and research institutions. The company maintains CLIA-waived status for certain molecular tests and holds FDA clearances and international regulatory approvals (CE marking). Manufacturing and distribution capabilities support North American and global markets.